Lilly boosts ADC portfolio with CrossBridge Bio deal
Worth up to $300 million, the buyout is Lilly’s latest of an ADC maker and adds technology for making “dual-payload” therapies.
Read the full article on the original site.
Read Full Article
Worth up to $300 million, the buyout is Lilly’s latest of an ADC maker and adds technology for making “dual-payload” therapies.
Read the full article on the original site.
Read Full Article